Key facts
- Microplate Dx’s last known valuation is $11.9M (Sep 2025).
- It has raised $14.0M across 2 recorded rounds; the latest was Seed Round ($645K) in Sep 2025.
- Notable investors include MedTech Innovator, Scottish Enterprise, Impact Venture, University of Strathclyde Endowment, Converge Challenge — 15 tracked in total.
- Microplate Dx has filed 2 Form Ds with the SEC since 2023, most recently Sep 2025 ($645K sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Microplate Dx
Funding rounds
2 roundsAbout Microplate Dx
Developer of a medical diagnostic device designed to reduce deaths from drug-resistant infections. The company's device offers a low-cost, accurate, point-of-care alternative to tackle antibiotic resistance and provide enhanced antibiotic stewardship, enabling patients to receive optimum antibiotic prescribing in under one hour.
- Sector
- Healthcare
- HQ
- Glasgow, United Kingdom
- Founded
- 2021
- Employees
- 15
- Website
- microplatedx.com/
- Ownership
- Privately Held (backing)
Microplate Dx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Microplate Dx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Microplate Dx in its N-PORT filings yet. We sweep new filings monthly.